Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 240

1.

Fine-mapping of a novel premenopausal breast cancer susceptibility locus at Chr4q31.22 in Caucasian women and validation in African and Chinese women.

Kumaran M, Ghosh S, Joy AA, Mackey JR, Cass CE, Zheng W, Yasui Y, Damaraju S.

Int J Cancer. 2019 May 14. doi: 10.1002/ijc.32407. [Epub ahead of print]

PMID:
31087647
2.

2-Nitroimidazole-Furanoside Derivatives for Hypoxia Imaging-Investigation of Nucleoside Transporter Interaction, 18F-Labeling and Preclinical PET Imaging.

Maier FC, Schweifer A, Damaraju VL, Cass CE, Bowden GD, Ehrlichmann W, Kneilling M, Pichler BJ, Hammerschmidt F, Reischl G.

Pharmaceuticals (Basel). 2019 Feb 15;12(1). pii: E31. doi: 10.3390/ph12010031.

3.

Role of cysteine 416 in N-ethylmaleimide sensitivity of human equilibrative nucleoside transporter 1 (hENT1).

Yao SYM, Ng AML, Cass CE, Young JD.

Biochem J. 2018 Oct 31;475(20):3293-3309. doi: 10.1042/BCJ20180543.

PMID:
30254099
4.

Multitargeted kinase inhibitors imatinib, sorafenib and sunitinib perturb energy metabolism and cause cytotoxicity to cultured C2C12 skeletal muscle derived myotubes.

Damaraju VL, Kuzma M, Cass CE, Putman CT, Sawyer MB.

Biochem Pharmacol. 2018 Sep;155:162-171. doi: 10.1016/j.bcp.2018.07.001. Epub 2018 Jul 2.

PMID:
29983397
5.

Breast cancer associated germline structural variants harboring small noncoding RNAs impact post-transcriptional gene regulation.

Kumaran M, Krishnan P, Cass CE, Hubaux R, Lam W, Yasui Y, Damaraju S.

Sci Rep. 2018 May 14;8(1):7529. doi: 10.1038/s41598-018-25801-1.

6.

Germline copy number variations are associated with breast cancer risk and prognosis.

Kumaran M, Cass CE, Graham K, Mackey JR, Hubaux R, Lam W, Yasui Y, Damaraju S.

Sci Rep. 2017 Nov 7;7(1):14621. doi: 10.1038/s41598-017-14799-7.

7.
8.

Synthesis and preclinical characterization of 1-(6'-deoxy-6'-[18F]fluoro-β-d-allofuranosyl)-2-nitroimidazole (β-6'-[18F]FAZAL) as a positron emission tomography radiotracer to assess tumor hypoxia.

Wanek T, Kreis K, Križková P, Schweifer A, Denk C, Stanek J, Mairinger S, Filip T, Sauberer M, Edelhofer P, Traxl A, Muchitsch VE, Mereiter K, Hammerschmidt F, Cass CE, Damaraju VL, Langer O, Kuntner C.

Bioorg Med Chem. 2016 Nov 1;24(21):5326-5339. doi: 10.1016/j.bmc.2016.08.053. Epub 2016 Aug 29.

PMID:
27614920
9.
10.

A Uridine Glucuronosyltransferase 2B7 Polymorphism Predicts Epirubicin Clearance and Outcomes in Early-Stage Breast Cancer.

Sawyer MB, Pituskin E, Damaraju S, Bies RR, Vos LJ, Prado CM, Kuzma M, Scarfe AG, Clemons M, Tonkin K, Au HJ, Koski S, Joy AA, Smylie M, King K, Carandang D, Damaraju VL, Hanson J, Cass CE, Mackey JR.

Clin Breast Cancer. 2016 Apr;16(2):139-44.e1-3. doi: 10.1016/j.clbc.2015.09.006. Epub 2015 Sep 25.

PMID:
26452313
11.

Inhibition of sodium-independent and sodium-dependent nucleobase transport activities by tyrosine kinase inhibitors.

Damaraju VL, Kuzma M, Cass CE, Sawyer MB.

Cancer Chemother Pharmacol. 2015 Nov;76(5):1093-8. doi: 10.1007/s00280-015-2859-8. Epub 2015 Sep 2.

PMID:
26330332
12.

Designing and Testing of Novel Taxanes to Probe the Highly Complex Mechanisms by Which Taxanes Bind to Microtubules and Cause Cytotoxicity to Cancer Cells.

St George M, Ayoub AT, Banerjee A, Churchill CD, Winter P, Klobukowski M, Cass CE, Ludueña RF, Tuszynski JA, Damaraju S.

PLoS One. 2015 Jun 8;10(6):e0129168. doi: 10.1371/journal.pone.0129168. eCollection 2015.

13.

Interactions of multitargeted kinase inhibitors and nucleoside drugs: Achilles heel of combination therapy?

Damaraju VL, Kuzma M, Mowles D, Cass CE, Sawyer MB.

Mol Cancer Ther. 2015 Jan;14(1):236-45. doi: 10.1158/1535-7163.MCT-14-0337. Epub 2014 Dec 17.

14.

Specimen quality evaluation in Canadian biobanks participating in the COEUR repository.

Le Page C, Köbel M, de Ladurantaye M, Rahimi K, Madore J, Babinszky S, Bachvarov DR, Bachvarova M, Beauchamp MC, Cass CE, Chadwick D, Colleen C, Damaraju S, Dufour J, Gotlieb WH, Kalloger SE, Portelance L, McAlpine JN, Matte I, Piché A, Shaw P, Roehrl MH, Vanderhyden BC, Watson PH, Huntsman DG, Provencher DM, Mes-Masson AM.

Biopreserv Biobank. 2013 Apr;11(2):83-93. doi: 10.1089/bio.2012.0044. Erratum in: Biopreserv Biobank. 2013 Aug;11(4):257. Roehrl, Michael H A [added].

PMID:
24845429
15.

Breast cancer prediction using genome wide single nucleotide polymorphism data.

Hajiloo M, Damavandi B, Hooshsadat M, Sangi F, Mackey JR, Cass CE, Greiner R, Damaraju S.

BMC Bioinformatics. 2013;14 Suppl 13:S3. doi: 10.1186/1471-2105-14-S13-S3. Epub 2013 Oct 1.

16.

Comparative in vitro evaluation of transportability and toxicity of capecitabine and its metabolites in cells derived from normal human kidney and renal cancers.

Damaraju VL, Mowles D, Wilson M, Kuzma M, Cass CE, Sawyer MB.

Biochem Cell Biol. 2013 Dec;91(6):419-27. doi: 10.1139/bcb-2013-0041. Epub 2013 Jun 17.

PMID:
24219283
17.

Erlotinib, gefitinib, and vandetanib inhibit human nucleoside transporters and protect cancer cells from gemcitabine cytotoxicity.

Damaraju VL, Scriver T, Mowles D, Kuzma M, Ryan AJ, Cass CE, Sawyer MB.

Clin Cancer Res. 2014 Jan 1;20(1):176-86. doi: 10.1158/1078-0432.CCR-13-2293. Epub 2013 Oct 29.

18.

Cellular influx, efflux, and anabolism of 3-carboranyl thymidine analogs: potential boron delivery agents for neutron capture therapy.

Sjuvarsson E, Damaraju VL, Mowles D, Sawyer MB, Tiwari R, Agarwal HK, Khalil A, Hasabelnaby S, Goudah A, Nakkula RJ, Barth RF, Cass CE, Eriksson S, Tjarks W.

J Pharmacol Exp Ther. 2013 Nov;347(2):388-97. doi: 10.1124/jpet.113.207464. Epub 2013 Sep 4.

19.

Expression of nucleoside transporters and deoxycytidine kinase proteins in muscle invasive urothelial carcinoma of the bladder: correlation with pathological response to neoadjuvant platinum/gemcitabine combination chemotherapy.

North S, El-Gehani F, Santos C, Ghosh S, Lai R, Cass CE, Mackey JR.

J Urol. 2014 Jan;191(1):35-9. doi: 10.1016/j.juro.2013.07.006. Epub 2013 Jul 10.

PMID:
23851183
20.

Assessing SNP-SNP interactions among DNA repair, modification and metabolism related pathway genes in breast cancer susceptibility.

Sapkota Y, Mackey JR, Lai R, Franco-Villalobos C, Lupichuk S, Robson PJ, Kopciuk K, Cass CE, Yasui Y, Damaraju S.

PLoS One. 2013 Jun 3;8(6):e64896. doi: 10.1371/journal.pone.0064896. Print 2014.

21.

Identification of a breast cancer susceptibility locus at 4q31.22 using a genome-wide association study paradigm.

Sapkota Y, Yasui Y, Lai R, Sridharan M, Robson PJ, Cass CE, Mackey JR, Damaraju S.

PLoS One. 2013 May 22;8(5):e62550. doi: 10.1371/journal.pone.0062550. Print 2013.

22.

Emerging transporters of clinical importance: an update from the International Transporter Consortium.

Hillgren KM, Keppler D, Zur AA, Giacomini KM, Stieger B, Cass CE, Zhang L; International Transporter Consortium.

Clin Pharmacol Ther. 2013 Jul;94(1):52-63. doi: 10.1038/clpt.2013.74. Epub 2013 Apr 8. Review.

23.

The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29.

Young JD, Yao SY, Baldwin JM, Cass CE, Baldwin SA.

Mol Aspects Med. 2013 Apr-Jun;34(2-3):529-47. doi: 10.1016/j.mam.2012.05.007. Review.

PMID:
23506887
24.

Human concentrative nucleoside transporter 3 transfection with ultrasound and microbubbles in nucleoside transport deficient HEK293 cells greatly increases gemcitabine uptake.

Paproski RJ, Yao SY, Favis N, Evans D, Young JD, Cass CE, Zemp RJ.

PLoS One. 2013;8(2):e56423. doi: 10.1371/journal.pone.0056423. Epub 2013 Feb 18.

25.

Transport of A1 adenosine receptor agonist tecadenoson by human and mouse nucleoside transporters: evidence for blood-brain barrier transport by murine equilibrative nucleoside transporter 1 mENT1.

Lepist EI, Damaraju VL, Zhang J, Gati WP, Yao SY, Smith KM, Karpinski E, Young JD, Leung KH, Cass CE.

Drug Metab Dispos. 2013 Apr;41(4):916-22. doi: 10.1124/dmd.112.049858. Epub 2013 Feb 6.

PMID:
23388705
26.

Germline DNA copy number aberrations identified as potential prognostic factors for breast cancer recurrence.

Sapkota Y, Ghosh S, Lai R, Coe BP, Cass CE, Yasui Y, Mackey JR, Damaraju S.

PLoS One. 2013;8(1):e53850. doi: 10.1371/journal.pone.0053850. Epub 2013 Jan 16.

27.

Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.

Maréchal R, Bachet JB, Mackey JR, Dalban C, Demetter P, Graham K, Couvelard A, Svrcek M, Bardier-Dupas A, Hammel P, Sauvanet A, Louvet C, Paye F, Rougier P, Penna C, André T, Dumontet C, Cass CE, Jordheim LP, Matera EL, Closset J, Salmon I, Devière J, Emile JF, Van Laethem JL.

Gastroenterology. 2012 Sep;143(3):664-674.e6. doi: 10.1053/j.gastro.2012.06.006. Epub 2012 Jun 13.

PMID:
22705007
28.

Role of human nucleoside transporters in the uptake and cytotoxicity of azacitidine and decitabine.

Damaraju VL, Mowles D, Yao S, Ng A, Young JD, Cass CE, Tong Z.

Nucleosides Nucleotides Nucleic Acids. 2012;31(3):236-55. doi: 10.1080/15257770.2011.652330.

PMID:
22356238
29.

A two-stage association study identifies methyl-CpG-binding domain protein 2 gene polymorphisms as candidates for breast cancer susceptibility.

Sapkota Y, Robson P, Lai R, Cass CE, Mackey JR, Damaraju S.

Eur J Hum Genet. 2012 Jun;20(6):682-9. doi: 10.1038/ejhg.2011.273. Epub 2012 Jan 18.

30.

Influence of sugar ring conformation on the transportability of nucleosides by human nucleoside transporters.

Damaraju VL, Mowles D, Smith KM, Yao SY, Young JD, Marquez VE, Cass CE.

Chembiochem. 2011 Dec 16;12(18):2774-8. doi: 10.1002/cbic.201100567. Epub 2011 Nov 4.

PMID:
22052809
31.

Biochemistry and biology of 2'-Fluoro-2'-deoxythymidine (FT), a putative highly selective substrate for thymidine kinase type 2 (TK2).

Wiebe LI, Sun W, Zhou A, Yang J, Sjuvarsson EV, Eriksson S, Paproski RJ, Cass CE, Kumar P, Knaus EE.

Curr Radiopharm. 2012 Jan;5(1):38-46.

PMID:
21864241
32.

Nucleobase transport by human equilibrative nucleoside transporter 1 (hENT1).

Yao SY, Ng AM, Cass CE, Baldwin SA, Young JD.

J Biol Chem. 2011 Sep 16;286(37):32552-62. doi: 10.1074/jbc.M111.236117. Epub 2011 Jul 27.

33.

Behavioral effects of elevated expression of human equilibrative nucleoside transporter 1 in mice.

Kost S, Sun C, Xiong W, Graham K, Cass CE, Young JD, Albensi BC, Parkinson FE.

Behav Brain Res. 2011 Oct 10;224(1):44-9. doi: 10.1016/j.bbr.2011.05.023. Epub 2011 May 27.

PMID:
21645551
34.

Up-regulation of P-glycoprotein confers acquired resistance to 6-mercaptopurine in human chronic myeloid leukemia cells.

Peng XX, Shi Z, Tiwari AK, Damaraju VL, Fu L, Cass CE, Ashby CR Jr, Kruh GD, Chen ZS.

Oncol Lett. 2011 May;2(3):549-556. Epub 2011 Mar 21.

35.

Nucleoside transporter gene expression in wild-type and mENT1 knockout mice.

Graham K, Yao S, Johnson L, Mowles D, Ng A, Wilkinson J, Young JD, Cass CE.

Biochem Cell Biol. 2011 Apr;89(2):236-45. doi: 10.1139/o10-152.

PMID:
21455274
36.

Potential novel candidate polymorphisms identified in genome-wide association study for breast cancer susceptibility.

Sehrawat B, Sridharan M, Ghosh S, Robson P, Cass CE, Mackey JR, Greiner R, Damaraju S.

Hum Genet. 2011 Oct;130(4):529-37. doi: 10.1007/s00439-011-0973-1. Epub 2011 Mar 19.

37.

Molecular biology of nucleoside transporters and their distributions and functions in the brain.

Parkinson FE, Damaraju VL, Graham K, Yao SY, Baldwin SA, Cass CE, Young JD.

Curr Top Med Chem. 2011;11(8):948-72. Review.

PMID:
21401500
38.

Interaction of fused-pyrimidine nucleoside analogs with human concentrative nucleoside transporters: High-affinity inhibitors of human concentrative nucleoside transporter 1.

Damaraju VL, Smith KM, Mowles D, Nowak I, Karpinski E, Young JD, Robins MJ, Cass CE.

Biochem Pharmacol. 2011 Jan 1;81(1):82-90. doi: 10.1016/j.bcp.2010.09.009. Epub 2010 Sep 18.

PMID:
20854794
39.

Biodistribution and uptake of 3'-deoxy-3'-fluorothymidine in ENT1-knockout mice and in an ENT1-knockdown tumor model.

Paproski RJ, Wuest M, Jans HS, Graham K, Gati WP, McQuarrie S, McEwan A, Mercer J, Young JD, Cass CE.

J Nucl Med. 2010 Sep;51(9):1447-55. doi: 10.2967/jnumed.110.076356. Epub 2010 Aug 18.

41.

Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma.

Maréchal R, Mackey JR, Lai R, Demetter P, Peeters M, Polus M, Cass CE, Salmon I, Devière J, Van Laethem JL.

Cancer. 2010 Nov 15;116(22):5200-6. doi: 10.1002/cncr.25303.

42.

Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC).

Santini D, Schiavon G, Vincenzi B, Cass CE, Vasile E, Manazza AD, Catalano V, Baldi GG, Lai R, Rizzo S, Giacobino A, Chiusa L, Caraglia M, Russo A, Mackey J, Falcone A, Tonini G.

Curr Cancer Drug Targets. 2011 Jan;11(1):123-9. Review.

PMID:
20578980
43.

Human nucleoside transporters: biomarkers for response to nucleoside drugs.

Damaraju VL, Sawyer MB, Mackey JR, Young JD, Cass CE.

Nucleosides Nucleotides Nucleic Acids. 2009 May;28(5):450-63. doi: 10.1080/15257770903044499. Review.

PMID:
20183595
44.

Predicting gemcitabine transport and toxicity in human pancreatic cancer cell lines with the positron emission tomography tracer 3'-deoxy-3'-fluorothymidine.

Paproski RJ, Young JD, Cass CE.

Biochem Pharmacol. 2010 Feb 15;79(4):587-95. doi: 10.1016/j.bcp.2009.09.025.

PMID:
19788890
45.

Evidence for copurification of micronuclei in sucrose density gradient-enriched plasma membranes from cell lines.

Damaraju S, Zhang N, Li N, Tao L, Damaraju VL, Dufour J, Santos C, Sun XJ, Mackey J, Wishart DS, Cass CE, Li L.

Anal Biochem. 2010 Jan 1;396(1):69-75. doi: 10.1016/j.ab.2009.08.019. Epub 2009 Aug 20.

PMID:
19699175
46.

Cytotoxic activity of gemcitabine in cultured cell lines derived from histologically different types of bladder cancer: role of thymidine kinase 2.

Damaraju S, Damaraju VL, Mowles D, Sawyer MB, Damaraju S, Cass CE.

Biochem Pharmacol. 2010 Jan 1;79(1):21-9. doi: 10.1016/j.bcp.2009.07.018. Epub 2009 Aug 4.

PMID:
19660438
47.

Predicting node positivity in gastric cancer from gene expression profiles.

Korenberg MJ, Dicken BJ, Damaraju S, Graham K, Cass CE.

Biotechnol Lett. 2009 Sep;31(9):1381-8. doi: 10.1007/s10529-009-0035-0. Epub 2009 May 30.

PMID:
19484188
48.

Conserved glutamate residues Glu-343 and Glu-519 provide mechanistic insights into cation/nucleoside cotransport by human concentrative nucleoside transporter hCNT3.

Slugoski MD, Smith KM, Ng AM, Yao SY, Karpinski E, Cass CE, Baldwin SA, Young JD.

J Biol Chem. 2009 Jun 19;284(25):17266-80. doi: 10.1074/jbc.M109.009613. Epub 2009 Apr 20.

49.

Substituted cysteine accessibility method analysis of human concentrative nucleoside transporter hCNT3 reveals a novel discontinuous region of functional importance within the CNT family motif (G/A)XKX3NEFVA(Y/M/F).

Slugoski MD, Ng AM, Yao SY, Lin CC, Mulinta R, Cass CE, Baldwin SA, Young JD.

J Biol Chem. 2009 Jun 19;284(25):17281-92. doi: 10.1074/jbc.M109.009704. Epub 2009 Apr 20.

50.

Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma.

Maréchal R, Mackey JR, Lai R, Demetter P, Peeters M, Polus M, Cass CE, Young J, Salmon I, Devière J, Van Laethem JL.

Clin Cancer Res. 2009 Apr 15;15(8):2913-9. doi: 10.1158/1078-0432.CCR-08-2080. Epub 2009 Mar 24.

Supplemental Content

Support Center